Biliary excretion of the vasopressin analogue DDAVP after intraduodenal, intrajugular and intraportal administration in the conscious pig.
The biliary excretion of the vasopressin analogue 1-deamino-8-D-arginine vasopressin (dDAVP) was determined in the pig after three administration routes, intrajugular venous, intraportal venous and intraduodenal. In all cases the biliary excretion was less than 1% of the administered dose. The plasma/bile concentration ratio was less than 1:1. A significant first-pass effect was found when the liver was exposed to a high intraportal dose of dDAVP. Possible uptake and degradation/biotransformation was evaluated by incubating [3H]dDAVP with liver tissue slices showing that [3H]dDAVP was rapidly removed from the incubation medium. The following conclusions can be drawn from these experiments: 1) The intestinal mucosa constitutes the major barrier to intestinal absorption of dDAVP. 2) dDAVP is excreted in bile in small amounts. 3) Indirect evidence suggests that the dDAVP molecule is degraded/biotransformed in the liver at its C-terminus.
Lundin
S
S
Department of Clinical Pharmacology, University of Lund, Sweden.
Pierzynovski
S G
SG
Weström
B R
BR
Bengtsson
H I
HI
D000818:Animals; D001646:Bile / Q000378:metabolism*; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004386:Duodenum; D066298:In Vitro Techniques; D007267:Injections; D007275:Injections, Intravenous; D007601:Jugular Veins; D008099:Liver / Q000378:metabolism; D008297:Male; D011169:Portal Vein; D013552:Swine
D003894:Deamino Arginine Vasopressin